NeuroSense reports 65% death risk reduction in ALS trial

Go back to NeuroSense reports 65% death risk reduction in ALS trial
(NASDAQ: NRSN) Delayed: 2.37 +0.04 (1.72%)
Previous Close $2.33    52 Week High $ 
Open $2.30    52 Week Low $ 
Day High $2.60    P/E N/A 
Day Low $2.28    EPS $ 
Volume 22,275       

(NASDAQ: NRSNW) Delayed: 0.01 --0 (-0%)
Previous Close $0.01    52 Week High $ 
Open $0.01    52 Week Low $ 
Day High $0.01    P/E N/A 
Day Low $0.01    EPS $ 
Volume 6